Policy Cures Research

What Policy Cures Research does

Policy Cures Research, now operating as Impact Global Health Ltd, is a private non-profit research organization that has tracked global health R&D funding and product development since 2007. Its core offering is the G-FINDER R&D Funding Portal, a longitudinal database covering neglected diseases, emerging infectious diseases, and maternal health, supplemented by the newly launched Product Pipeline Portal (March 2026), the Innovation Spillover Tracker, the Snakebite Envenoming Medicines Database, and analytical frameworks including the Impact Framework and the 100 Days Mission Scorecard (co-developed with the International Pandemic Preparedness Secretariat). The organization also publishes analytical reports such as The Ripple Effect 3.0, which provides country-specific case studies on the domestic benefits of global health R&D investments.

The underlying technology is a data aggregation and analytics platform built around self-service web portals that let users explore funding flows and product pipelines without direct sales interaction. A Global Advisory Council of leading global health figures supports strategic direction, and the organization maintains formal partnerships with PATH (R&D Blindspots Policy Series focused on Africa) and the International Pandemic Preparedness Secretariat. Headcount is in the 11–50 range and the entity is a UK-incorporated private limited company, with a presence in Surry Hills, Australia.

Revenue mechanics are not publicly disclosed but appear to combine data monetisation via report and portal access with commissioned analytical expertise and partnerships with global health funders. The customer base spans global health funders and investors, policymakers and government agencies, product developers and researchers, and advocacy organizations and NGOs. Pricing is not published and no named customer logos, contracts, or revenue splits are available.

Name

Policy Cures Research

Legal name

Impact Global Health Ltd

Website

https://policycuresresearch.org

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

11–50 employees

Short description

Policy Cures Research (now Impact Global Health) is a non-profit research organization that operates gold-standard data portals tracking global health R&D funding and product pipelines since 2007, serving funders, policymakers, product developers, and advocacy organizations worldwide.

Ownership category

akta.pro rank

Product category

Global Health R&D Analytics

NAICS

Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Global Health Research, Evidence & Technical Assistance Organizations (HLAJAKAN)

akta.pro secondary industries

Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM), Disease-Specific Global Programs (HIV/TB/Malaria/NTDs) (HLAJAKAF), Communicable Disease Prevention & Control (HIV/AIDS, TB, Malaria, NTDs) (BPADAIAA)

Keywords

• Global health R&D
• R&D funding analysis
• Product pipeline tracking
• Health policy research
• Pharmaceutical R&D data

Headquarters

HQ city

Surry Hills

HQ country

Australia

HQ region

Oceania

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations

Revenue model

1. Data access and reports: Provides data portals and analytical reports on global health R&D funding and product pipelines. Revenue appears to come from commissioned expertise, report sales, and partnerships with funding organizations.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Policy Cures Research (operating as Impact Global Health) operates a portfolio of interactive data portals, analytical databases, and policy research products that track global investment in health product R&D and the resulting product development pipelines. Core offerings cover neglected disease R&D funding, product pipeline tracking, innovation spillover between disease areas, snakebite envenoming medicines, the 100 Days Mission response scorecard, and impact measurement frameworks for women's health and emerging infectious diseases. Customers are institutional funders, policymakers, multilateral agencies, advocacy organisations, and product developers.

Product overview

Policy Cures Research (now operating as Impact Global Health) offers a suite of interconnected data platforms and analytical tools for global health R&D. The core offerings include the G-FINDER R&D Funding Portal, which tracks funding for neglected diseases and emerging infectious diseases since 2007, and the Product Pipeline Portal, which maps the end-to-end R&D pipeline from investigational candidates to approved products. Supporting these are the Innovation Spillover Tracker and Snakebite Envenoming Medicines Database. The company also provides analytical frameworks including the Impact Framework for assessing global health R&D effectiveness and the 100 Days Mission Scorecard for pandemic preparedness readiness. Reports such as The Ripple Effect 3.0 deliver quantitative case studies on the domestic benefits of global health investments.

Differentiator

Problem solved

Functional benefit

Brands

• G-FINDER: Gold-standard database tracking R&D funding for neglected diseases, emerging infectious diseases, and maternal health since 2007.

Products and services

• G-FINDER R&D Funding Portal Interactive portal providing longitudinal data on global R&D funding flows for neglected diseases, used by funders, policymakers, and product developers to benchmark investment.
• Product Pipeline Portal

Quantifiable outcome

• UK institutions involved in R&D for 20% of malaria tools currently in the pipeline (third highest of any country)

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Two partnerships are on record, tiered core.

• PATHcoreStrategic or Co-development PartnerImpact Global Health and PATH are joining forces to provide decision-makers with clarity and evidence on critical global health choices, with a focus on Africa. The partnership produces the R&D Blindspots Policy Series.
• International Pandemic Preparedness SecretariatcoreStrategic or Co-development PartnerCollaborated on developing the 100 Days Mission Scorecard, which assesses global readiness to deploy new products to tackle epidemics within 100 days of an outbreak.

Scale indicators3 records

Recent moves5 records

Expansion highlights6 records

Broad incumbents

• Wellcome Trust: Wellcome is a major global health funder and convener that publishes independent research and analyses on R&D investment, sharing the evidence-generation mandate Impact Global Health plays in the funder ecosystem.
• Gavi, the Vaccine Alliance: Gavi finances vaccine procurement and introduction for LMICs and is a major actor in the global health R&D and immunization pipeline that Impact Global Health's pipeline portal tracks and analyzes.
• WHO (World Health Organization): WHO is the UN's global health authority producing R&D landscape analyses, financing data, and pipeline tracking. It overlaps with Impact Global Health's evidence and pipeline intelligence work but at much broader policy and normative scope.
• The Global Fund to Fight AIDS, Tuberculosis and Malaria: The Global Fund is a major financing institution for HIV/TB/malaria and a primary data contributor to G-FINDER, operating as a large-scale incumbent in the same R&D and funding landscape Impact Global Health analyzes.

Emerging players

• IAVI (International AIDS Vaccine Initiative): IAVI is a product development partnership focused on HIV vaccine and antibody R&D, part of the PDP ecosystem that G-FINDER tracks as both a funding recipient and pipeline contributor.
• Treatment Action Group (TAG): TAG is a research and advocacy organization focused on HIV, TB, and HCV, using data-driven analysis to push for increased R&D funding — a comparable data-and-advocacy niche player.

Direct peers

• PATH: PATH is both a strategic partner (R&D Blindspots Policy Series) and a direct peer operating across global health product development, with overlapping focus on neglected diseases, maternal health, and African decision-maker engagement.
• Drugs for Neglected Diseases initiative (DNDi): DNDi is a product development partnership focused on neglected disease R&D, operating in the same disease areas covered by G-FINDER and tracking similar pipeline and funding themes for HIV/TB/malaria/NTDs.
• Coalition for Epidemic Preparedness Innovations (CEPI): CEPI funds and coordinates vaccine R&D for emerging infectious diseases — the same area covered by G-FINDER's emerging infectious disease tracking and the 100 Days Mission Scorecard partnership.

Regional players

• Unitaid: Unitaid invests in global health R&D across HIV, TB, malaria, and women's health — intersecting directly with the disease verticals and product pipeline that Impact Global Health's platforms map.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/PCuresResearch
• LinkedInlinkedin.com/company/policy-cures-research

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Policy Cures Research